4 patents
Utility
ANTI-TNFR2 Antibodies and Uses Thereof
8 Sep 22
Disclosed herein are anti-TNFR2 antibodies, therapeutic compositions comprising the anti-TNFR2 antibodies, and methods of using such antibodies and compositions in the treatment of cancer and autoimmune diseases.
Yu ZHOU, James D. MARKS, Marco MUDA, James Frank SAMPSON, Eric M. TAM, Ross Bane FULTON
Filed: 28 Feb 20
Utility
ANTI-TNFR2 Antibodies and Uses Thereof
2 Dec 21
Anti-TNFR2 antibodies which bind to particular human TNFR2 epitopes, therapeutic compositions comprising the anti-TNFR2 antibodies, and methods of using such antibodies and compositions in the treatment of cancer are disclosed.
Eric M. TAM, Marco MUDA, Klaus Andreas RAUE, Vinodh B. KURELLA, Daryl Clark DRUMMOND, Ross Bane FULTON, Fabien DEPIS, Anne-Sophie DUGAST, Jian TANG, Sandeep KUMAR
Filed: 18 Sep 19
Utility
Inhibiting ataxia telangiectasia and Rad3-related protein (ATR)
24 Feb 20
Novel compounds inhibiting ATR protein kinase include compounds of formula (I) disclosed herein, as well as liposome formulations comprising ATR protein kinase inhibitor compounds.
Daryl C. Drummond, Bolin Geng, Dmitri B. Kirpotin, Suresh K. Tipparaju, Alexander Koshkaryev, Ozan Alkan
Filed: 10 Jan 17
Utility
Nanoliposomal Targeting of Ephrin Receptor A2 (Epha2) and Related Diagnostics
2 Oct 19
EphA2 targeted doxorubicin generating nano-liposomes are useful in the treatment of EphA2 positive cancer comprising cancer cells expressing over about 3000 EphA2 receptors/cell.
Daryl C. Drummond, Dmitri B. Kirpotin, Walid Kamoun
Filed: 15 Mar 17
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first